Non adatto a bambini, donne in gravidanza o allattamento
Learn more or start with a visit to Doctronic.ai
During the first year, the average weight loss in the orlistat-treated group was 23.3 pounds (10.6 kg), while the placebo group lost only 13.6 pounds (6.2 kg)
This pain may understandably discourage physical activity
Reported and plausible concerns Finally, Nausea, flushing, headache, fatigue, yawning, and appetite changes Consequently, Spontaneous erections and possible priapism For example, Generalized darkening and changes in freckles or existing moles Moreover, Uncertain long-term melanocyte and melanoma-related risk In addition, Unknown cardiovascular, endocrine, reproductive, and drug-interaction effects However, Contamination or dosing variability in unregulated products Current evidence does not prove that Melanotan II directly causes melanoma
doi:10.3803/EnM.2024.501 29